Alnylam Heart Drug Approval Sets Up Challenge With Pfizer
Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old ...
Why Pfizer Is My Largest Healthcare Position
Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...
Pfizer Is Trading As If It's 2009 Again
Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...
Fierce Pharma2d
AstraZeneca, Pfizer rebuked over breaking UK drug marketing rules on LinkedIn use
The PMCPA has dug into the industry’s LinkedIn activities once again. | The PMCPA has dug into the industry’s LinkedIn ...
Pfizer: Undervalued Defensive Play
With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...
Viagra was approved by the FDA 27 years ago. It changed how we talk about sex.
Viagra was approved by the U.S. Food and Drug Administration 27 years ago. Experts say it immediately changed the way we talk ...
8 AI Drug Discovery and Manufacturing Stocks to Buy
Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...
Why cheaper alternatives to weight-loss drugs like Wegovy, Zepbound will be tougher to get
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...
MedCity News6d
Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma
Amvuttra is the third medication approved for ATTR cardiomyopathy, behind products from Pfizer that have become the standard of care and a BridgeBio Pharma drug approved last fall. But Amvuttra ...